NICE Approves First NHS Treatment for Advanced Hodgkin Lymphoma

Introduction

In a landmark decision, NICE has approved the first routine NHS treatment for adults with stage 3 or 4 CD30-positive Hodgkin lymphoma who have not received prior therapy. The new recommendation endorses brentuximab vedotin (Adcetris) in combination with doxorubicin, vinblastine, and dacarbazine.

This decision follows clinical trial results demonstrating that the combination therapy significantly improves outcomes compared with existing standard treatments.

Clinical Trial Evidence

The recommendation is supported by data from the ECHELON-1 trial, which showed that the brentuximab-based combination delays disease progression and enhances overall survival in patients with advanced Hodgkin lymphoma. These findings suggest a meaningful advance in treatment effectiveness for a group historically facing limited first-line options.

Patient Access and Implementation

The treatment will be made available through the Cancer Drugs Fund with immediate effect. Interim funding is in place to ensure access while routine NHS commissioning arrangements are finalised.

Helen Knight, Director of Medicines Evaluation at NICE, stated:
“This treatment option offers patients more time before their disease gets worse and more time to spend with their loved ones.”

Conclusion

The approval of brentuximab vedotin in combination with chemotherapy represents a significant step forward in treating advanced Hodgkin lymphoma. With improved survival outcomes and NHS access secured, this decision marks a new era in care for patients with this aggressive disease.

Citation:
National Institute for Health and Care Excellence. (2025, March 28). First ever NHS treatment approved for advanced Hodgkin lymphoma. NICE.